Other targeted drugs that have recently been shown to have efficacy in the setting of an indentified genomic aberration include vismodegib in advanced basal cell skin cancers harboring mutations in PTCH1, and vemurafenib in patients with advanced melanoma exhibiting a V600E mutation in the BRAF (v-raf murine sarcoma viral oncogene homolog B1) gene product [4,5]. The gene discussed is BRAF; the disease is skin basal cell carcinoma.